Clinical trial
Complete Pathological Response Prediction After Neoadjuvant Treatment Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.
NCT01984866 is registered in ClinicalTrials.gov with Hospital General Universitario Gregorio Marañon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Complete Pathological Response Prediction After Neoadjuvant Treatment Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.
- Lead sponsor
- Hospital General Universitario Gregorio Marañon
- Phase
- Observational
- Overall status
- Terminated
- Start date
- July 31, 2013
- Completion date
- August 31, 2018
- Enrollment
- 13 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
triple negative, her2+, luminal b breast tumors (stages ii-iii)in female patients